ASO Visual Abstract: Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy
(Source: Annals of Surgical Oncology)
Source: Annals of Surgical Oncology - April 6, 2024 Category: Cancer & Oncology Source Type: research
ASO Visual Abstract: Completely Resectable (cT1-2) Esophageal Squamous Cell Carcinoma with Minimal Lymph Node Involvement (cN1): Is Neoadjuvant Chemoradiation Therapy the Only Viable Treatment Option?
(Source: Annals of Surgical Oncology)
Source: Annals of Surgical Oncology - April 6, 2024 Category: Cancer & Oncology Source Type: research
Comprehensive single-cell transcriptomic profiling reveals molecular subtypes and prognostic biomarkers with implications for targeted therapy in esophageal squamous cell carcinoma
CONCLUSIONS: This integrated single-cell sequencing analysis provides new insights into the molecular heterogeneity and prognostic determinants underlying ESCC. The findings identify potential prognostic biomarkers and a gene expression signature that may enable improved patient risk stratification in ESCC. Experimental validation of the role of PRKCB substantiates the potential clinical utility of our results.PMID:38582059 | DOI:10.1016/j.tranon.2024.101948 (Source: Translational Oncology)
Source: Translational Oncology - April 6, 2024 Category: Cancer & Oncology Authors: Dengfeng Zhang Fangchao Zhao Jing Li Pengfei Guo Haitao Liu Tianxing Lu Shujun Li Zhirong Li Yishuai Li Source Type: research
PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study
CONCLUSIONS: The combination of PD-1 inhibitors and chemotherapy as first-line treatment for ESCC patients with distant metastasis still has good efficacy and safety compared to clinical trials in the real world.PMID:38576619 | PMC:PMC10993248 | DOI:10.3389/fimmu.2024.1353445 (Source: Cancer Control)
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Loulu Gao Lin Tang Jieqiong Peng Zixuan Hu Jing Yang Bo Liu Source Type: research
Whole-process case management effects on mental state and self-care ability in patients with liver cancer
CONCLUSION: Whole-process case management can effectively reduce anxiety and depression in patients with liver cancer, alleviate symptoms and problems, and improve the level of hope, self-care ability, sleep quality, and quality of life, as well as provide feasible nursing alternatives for patients with liver cancer.PMID:38577082 | PMC:PMC10989342 | DOI:10.4240/wjgs.v16.i3.833 (Source: Cancer Control)
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Man-Di Ju Qin Qin Meng Li Source Type: research
circular RNA circ-231 promotes protein biogenesis of TPI1 and PRDX6 through mediating the interaction of eIF4A3 with STAU1 to facilitate unwinding of secondary structure in 5' UTR, enhancing progression of human esophageal squamous cell carcinoma (ESCC)
Conclusions: Our data unravels the detailed mechanism by which STAU1 binds to secondary structure in 5' UTR of mRNAs and recruits eIF4A3 through interacting with circ-231 and thereby eIF4A3 is implicated in unwinding of secondary structure, which is common to HEK293T and ESCC. However, importantly, our data reveals that circ-231 promotes migration and proliferation of ESCC and the up-regulated circ-231 greatly correlates with tumor lymph node metastasis, insinuating that circ-231 could be a therapeutic target and an indicator of risk of lymph node metastasis for patients with ESCC.PMID:38577609 | PMC:PMC10988296 | DOI:10.7...
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Guo-Wei Huang Ti-Qun Yang Qian-Qian Chen Xing-Mu Liu Ling-Hui Xie Wei Huang Xue-Ling Chen Yi-Qun Geng Jiang Gu Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine)
Source: Molecular Medicine - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology
CONCLUSION: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.PMID:38578596 | DOI:10.1007/s10147-024-02502-6 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Mamoru Ito Yuta Okumura Kenta Nio Eishi Baba Yukinori Ozaki Hiroshi Nishio Eiki Ichihara Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Nobuaki Ochi Toshio Kubo Keita Uchino Takahiro Source Type: research
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology
CONCLUSION: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.PMID:38578596 | DOI:10.1007/s10147-024-02502-6 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Mamoru Ito Yuta Okumura Kenta Nio Eishi Baba Yukinori Ozaki Hiroshi Nishio Eiki Ichihara Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Nobuaki Ochi Toshio Kubo Keita Uchino Takahiro Source Type: research
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology
CONCLUSION: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.PMID:38578596 | DOI:10.1007/s10147-024-02502-6 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Mamoru Ito Yuta Okumura Kenta Nio Eishi Baba Yukinori Ozaki Hiroshi Nishio Eiki Ichihara Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Nobuaki Ochi Toshio Kubo Keita Uchino Takahiro Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine)
Source: Molecular Medicine - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
